JP2023502780A5 - - Google Patents

Info

Publication number
JP2023502780A5
JP2023502780A5 JP2022530237A JP2022530237A JP2023502780A5 JP 2023502780 A5 JP2023502780 A5 JP 2023502780A5 JP 2022530237 A JP2022530237 A JP 2022530237A JP 2022530237 A JP2022530237 A JP 2022530237A JP 2023502780 A5 JP2023502780 A5 JP 2023502780A5
Authority
JP
Japan
Prior art keywords
agonist
item
population
til
tils
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2022530237A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023502780A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/062094 external-priority patent/WO2021108455A1/en
Publication of JP2023502780A publication Critical patent/JP2023502780A/ja
Publication of JP2023502780A5 publication Critical patent/JP2023502780A5/ja
Priority to JP2025133444A priority Critical patent/JP2025159098A/ja
Withdrawn legal-status Critical Current

Links

JP2022530237A 2019-11-25 2020-11-24 腫瘍浸潤リンパ球の活性化及び増殖方法 Withdrawn JP2023502780A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025133444A JP2025159098A (ja) 2019-11-25 2025-08-08 腫瘍浸潤リンパ球の活性化及び増殖方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962940035P 2019-11-25 2019-11-25
US62/940,035 2019-11-25
US202063081539P 2020-09-22 2020-09-22
US63/081,539 2020-09-22
PCT/US2020/062094 WO2021108455A1 (en) 2019-11-25 2020-11-24 Methods for activation and expansion of tumor infiltrating lymphocytes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025133444A Division JP2025159098A (ja) 2019-11-25 2025-08-08 腫瘍浸潤リンパ球の活性化及び増殖方法

Publications (2)

Publication Number Publication Date
JP2023502780A JP2023502780A (ja) 2023-01-25
JP2023502780A5 true JP2023502780A5 (enExample) 2023-12-01

Family

ID=76128945

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022530237A Withdrawn JP2023502780A (ja) 2019-11-25 2020-11-24 腫瘍浸潤リンパ球の活性化及び増殖方法
JP2025133444A Pending JP2025159098A (ja) 2019-11-25 2025-08-08 腫瘍浸潤リンパ球の活性化及び増殖方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025133444A Pending JP2025159098A (ja) 2019-11-25 2025-08-08 腫瘍浸潤リンパ球の活性化及び増殖方法

Country Status (8)

Country Link
US (1) US20240376428A1 (enExample)
EP (1) EP4065233A4 (enExample)
JP (2) JP2023502780A (enExample)
KR (1) KR20220119038A (enExample)
CN (1) CN115003387A (enExample)
AU (1) AU2020392094A1 (enExample)
CA (1) CA3162272A1 (enExample)
WO (1) WO2021108455A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020180882A1 (en) 2019-03-05 2020-09-10 Nkarta, Inc. Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
US12365871B2 (en) 2020-04-28 2025-07-22 Lyell Immunopharma, Inc. Methods for culturing cells
WO2021252804A1 (en) 2020-06-12 2021-12-16 Nkarta, Inc. Genetically modified natural killer cells for cd70-directed cancer immunotherapy
CN116948964A (zh) 2020-11-19 2023-10-27 苏州沙砾生物科技有限公司 肿瘤浸润淋巴细胞的培养方法及其用途
US20240360410A1 (en) * 2021-08-03 2024-10-31 Suzhou Grit Biotechnology Co., Ltd. Modified tumor infiltrating lymphocyte and use thereof
KR20240052771A (ko) * 2021-09-08 2024-04-23 케이에스큐 세러퓨틱스 인코포레이티드 림프구 효력 검정
WO2023125772A1 (zh) * 2021-12-30 2023-07-06 苏州沙砾生物科技有限公司 一种修饰的肿瘤浸润淋巴细胞及其用途
CN118525084A (zh) * 2022-01-19 2024-08-20 苏州沙砾生物科技有限公司 肿瘤浸润淋巴细胞在疾病治疗中的用途
EP4469068A4 (en) * 2022-01-28 2026-05-13 Abelzeta Inc TUMOR-INFILTRATING LYMPHOCYTE ENRICHEMENT PROCESS
EP4471128A4 (en) * 2022-01-29 2026-03-04 Suzhou Grit Biotechnology Co Ltd Modified tumor infiltrating lymphocyte and use thereof
JP2025508050A (ja) * 2022-03-07 2025-03-21 ンカルタ・インコーポレイテッド Ｃｄ７０指向性がん免疫療法のための多重遺伝子編集細胞
CN117417894A (zh) * 2023-09-15 2024-01-19 毕诺济(上海)生物技术有限公司 敲除Roquin-1和/或Regnase-1基因的肿瘤浸润淋巴细胞及其应用
WO2025092690A1 (zh) * 2023-10-30 2025-05-08 苏州沙砾生物科技有限公司 一种修饰的细胞及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006112869A2 (en) * 2004-07-19 2006-10-26 Baylor College Of Medicine Modulation of cytokine signaling regulators and applications for immunotherapy
JPWO2010098429A1 (ja) * 2009-02-27 2012-09-06 国立大学法人大阪大学 免疫アジュバント組成物、及びその利用
EP2711418B1 (en) * 2012-09-25 2017-08-23 Miltenyi Biotec GmbH Method for polyclonal stimulation of T cells by flexible nanomatrices
US20170224731A1 (en) * 2014-06-10 2017-08-10 Monash University Method of producing leukocytes using ptpn2 inhibition for adoptive cell transfer
ES2808914T3 (es) * 2014-09-04 2021-03-02 Stemcell Tech Inc Complejos de anticuerpo solubles para la activación y expansión de linfocitos T o células NK
CN107567461A (zh) * 2014-12-29 2018-01-09 诺华股份有限公司 制备嵌合抗原受体表达细胞的方法
AU2016249005B2 (en) * 2015-04-17 2022-06-16 Novartis Ag Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
WO2017087768A1 (en) * 2015-11-18 2017-05-26 Duke University Targeted delivery of interleukin-10 to tumor infiltrating lymphocytes
TWI788307B (zh) * 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
MA50871A (fr) * 2017-05-10 2020-03-18 Iovance Biotherapeutics Inc Expansion de lymphocytes infiltrant des tumeurs à partir de tumeurs liquides et leurs utilisations thérapeutiques
KR20200130826A (ko) * 2018-03-15 2020-11-20 케이에스큐 세러퓨틱스 인코포레이티드 개선된 면역요법을 위한 유전자-조절 조성물 및 방법
WO2019178420A1 (en) * 2018-03-15 2019-09-19 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
CN108753718A (zh) * 2018-06-20 2018-11-06 淮安诺康生物科技有限公司 肿瘤浸润淋巴细胞til的体外扩增方法

Similar Documents

Publication Publication Date Title
JP2023516300A5 (enExample)
Jung et al. BLIMP1 and NR4A3 transcription factors reciprocally regulate antitumor CAR T cell stemness and exhaustion
US20230108584A1 (en) Methods for activation and expansion of tumor infiltrating lymphocytes
TW202538050A (zh) 製備表現嵌合抗原受體的細胞之方法
JP2023502780A (ja) 腫瘍浸潤リンパ球の活性化及び増殖方法
US20190167720A1 (en) Gene editing for immunological destruction of neoplasia
US11957695B2 (en) Methods and compositions targeting glucocorticoid signaling for modulating immune responses
CN116656605A (zh) 用于扩增细胞群的方法、试剂盒及装置
US11793787B2 (en) Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
CN111684061A (zh) 表达嵌合抗原受体的调节性t细胞
CN119614577A (zh) 用于细胞靶向和标记的抗cd3核酸适配体
Joshi et al. Activating the antitumor immune response in non‐Hodgkin lymphoma using immune checkpoint inhibitors
JP7043114B2 (ja) 細胞を活性化させるための方法およびキット
KR20230124983A (ko) 유전적으로 조작된 세포를 추적하기 위한 펩타이드마커
JP2023526278A (ja) 組み換え受容体を発現しているドナーバッチ細胞を産生するための方法
CA3005878A1 (en) Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
US20230381313A1 (en) CD16high CD57high NK-92MI Cells
US20200317780A1 (en) METHODS FOR ENHANCING TCRab+ CELL DEPLETION
AU2021402100A9 (en) Chimeric antigen receptor (car) spacer modifications enhance car t cell functionality
JP7524210B2 (ja) Ｃｄ２８ ｔ細胞培養物、組成、およびその使用方法
HK40115099A (zh) Cp16高cp57高nk-92mi细胞
Alsheikh et al. Direct contact with natural killer cells reprograms monocyte-derived dendritic cells into a tolerogenic phenotype
RU2778411C2 (ru) Способы культивирования клеток и наборы и устройство для них
CN116888148A (zh) 追踪基因工程化细胞的肽标志物
Olive et al. Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome